1. Scrip
  3. >>Anticancer

CAR-T Forecast: Celgene Follows, But Also Leads As Next Batch Of T-Cell Therapies Near Market

 
• By Mandy Jackson

Celgene's lead program will be the third autologous CD19-targeting T-cell therapy on the market, but the company is in the lead among BCMA-targeting CAR-T candidates. Next-generation technologies are also on the way.

3D illustration of T cells attacking a cancer cell (CAR-T cell therapy) - Illustration

With the first chimeric antigen receptor T-cell (CAR-T) therapies on the market and making headway, the next wave of development is advancing, with next-generation technologies including allogeneic therapies and CAR-T cells with an on/off switch looking to take the stage.

Celgene Corp

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

More from Anticancer